Article
Medicine, Research & Experimental
Sabrina Kraus, Philipp Klassen, Malte Kircher, Alexander Dierks, Stefan Habringer, Alexander Gaeble, Klaus Martin Kortuem, Niels Weinhold, Valeeza Ademaj-Kospiri, Rudolf A. Werner, Andreas Schirbel, Andreas K. Buck, Peter Herhaus, Hans-Juergen Wester, Andreas Rosenwald, Wolfgang A. Weber, Hermann Einsele, Ulrich Keller, Leo Rasche, Constantin Lapa
Summary: This study evaluates the prognostic impact of splenic CXCR4 expression in patients with multiple myeloma (MM). The findings suggest that splenic Ga-68-Pentixafor uptake is associated with disease progression, treatment history, and clinical outcome. Reduced splenic uptake is linked to unfavorable prognosis and can serve as an independent predictor of survival.
Article
Oncology
Philipp Linde, Christian Baues, Simone Wegen, Maike Trommer, Alexander Quaas, Johannes Rosenbrock, Eren Celik, Simone Marnitz, Christiane J. Bruns, Thomas Fischer, Klaus Schomaecker, Hans-Juergen Wester, Alexander Drzezga, Lutz van Heek, Carsten Kobe
Summary: The expression of CXCR4 in solid tumors plays a key role in tumor growth and metastasis. This study compared the use of FDG-PET/CT and Pentixafor-PET/CT in esophageal cancer patients, showing differences in lesion identification and suggesting that Pentixafor PET/CT could serve as a complementary tool in radiation treatment.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yinjie Gao, Jie Ding, Yunying Cui, Tianyi Li, Hao Sun, Dachun Zhao, Yushi Zhang, Li Huo, Anli Tong
Summary: Ga-68-pentixafor PET/CT shows high sensitivity and specificity in the diagnosis of functional nodules in primary aldosteronism. It performs better in detecting nodules with a diameter greater than 1 cm.
EUROPEAN RADIOLOGY
(2023)
Article
Medicine, Research & Experimental
Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Verena Pichler, Sarah Pfaff, Michael Weber, Barbara Kiesewetter, Markus Hacker, Lukas Kazianka, Philipp B. Staber, Hans-Juergen Wester, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Alexander Haug
Summary: In this prospective study, [Ga-68]Pentixafor-PET showed higher sensitivity and detection rates compared to [F-18]FDG-PET in patients with mantle cell lymphoma (MCL), indicating that it may be a potential alternative for imaging in these patients. The study also found that SUVs and TBRs were significantly higher for [Ga-68]Pentixafor-PET, with the most notable difference observed in mean TBRblood values.
Review
Oncology
Domenico Albano, Francesco Dondi, Francesco Bertagna, Giorgio Treglia
Summary: Preliminary evidence suggests that [Ga-68]Ga-Pentixafor PET/CT or PET/MRI may have a useful impact in lymphoma, particularly in FDG-not-avid variants. This systematic review aimed to analyze published data on the role of [Ga-68]Ga-Pentixafor PET/CT or PET/MRI in lymphoma, with a focus on different lymphoma variants and clinical applications. The findings indicate that [Ga-68]Ga-Pentixafor PET can be considered a valuable imaging method for staging and evaluating treatment response in multiple lymphomas, including MZL, CNSL, and LPL. There is also evidence to suggest that [Ga-68]Ga-Pentixafor PET may have better diagnostic performance than [F-18]FDG PET in assessing lymphomas.
Article
Radiology, Nuclear Medicine & Medical Imaging
Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li, Fang Li
Summary: Ga-68-pentixafor PET/CT outperforms F-18-FDG PET/CT in response assessment of WM/LPL, showing different tumor responses and detecting disease progression more effectively.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Amit Singh Shekhawat, Baljinder Singh, Pankaj Malhotra, Ankit Watts, Rajender Basher, Harneet Kaur, Monika Hooda, Bishan D. Radotra
Summary: In this study, the diagnostic utility of Ga-68-Pentixafor PET/CT in multiple myeloma was evaluated. The results showed that it can more accurately assess CXCR4 expression and disease extent compared to F-18-FDG PET/CT, with higher TBRmax values. Additionally, Ga-68-Pentixafor PET/CT can detect extramedullary and medullary lesions. Therefore, this technique has potential importance in the diagnosis and staging of multiple myeloma.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Article
Biology
Xia Lu, Raffaella Calabretta, Wolfgang Wadsak, Alexander R. Haug, Marius Mayerhoefer, Markus Raderer, Xiaoli Zhang, Jingle Li, Marcus Hacker, Xiang Li
Summary: This study compared the uptake of [Ga-68]PentixaFor and [F-18]FDG in arterial lesions and found that [Ga-68]PentixaFor PET/MRI identified more lesions and showed higher uptake. It also revealed an increased uptake of [Ga-68]PentixaFor in patients with high-risk cardiovascular factors and a correlation between elevated uptake in active arterial segments and the heart.
Article
Radiology, Nuclear Medicine & Medical Imaging
Sarah M. Jacobs, Pieter Wesseling, Bart de Keizer, Nelleke Tolboom, F. F. Tessa Ververs, Gerard C. Krijger, Bart A. Westerman, Tom J. Snijders, Pierre A. Robe, Anja G. van der Kolk
Summary: CXCR4 is found to be overexpressed in multiple human cancer types but is low or absent in healthy tissue. In glioblastoma, it is associated with poor prognosis. The study aimed to investigate CXCR4 expression in glioblastoma tissue using PET agents and found a subset of tumors with high CXCR4 expression may be good candidates for targeted radionuclide therapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ankit Watts, Baljinder Singh, Harmandeep Singh, Amanjit Bal, Harneet Kaur, Ninjit Dhanota, Sunil K. Arora, Bhagwant R. Mittal, Digambar Behera
Summary: In vivo quantification of CXCR4 receptors in different lung cancer sub-types using [Ga-68]Ga-Pentixafor PET/CT showed higher expression in small cell lung cancer patients compared to non-small cell lung cancer and lung neuroendocrine neoplasm patients. The study also demonstrated a significant correlation between SUVmax and MFI values in squamous cell NSCLC and NSCLC adenocarcinoma, supporting the specific in vivo uptake of [Ga-68]Ga-Pentixafor by CXCR4 receptors as a potential tool for response assessment and development of CXCR4-based radioligand therapies in lung cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Niklas Dreher, Stefanie Hahner, Carmina T. Fuss, Wiebke Schloetelburg, Philipp E. Hartrampf, Sebastian E. Serfling, Andreas Schirbel, Samuel Samnick, Takahiro Higuchi, Alexander Weich, Constantin Lapa, Andreas Rosenwald, Andreas K. Buck, Stefan Kircher, Rudolf A. Werner
Summary: This study aimed to characterize the in-vivo CXCR4 expression in patients with solid tumors and compare it to ex-vivo findings. The results showed that a substantial proportion of prevalent solid tumors demonstrated increased and uniform [(68)Ga]Ga-pentixafor uptake, indicating high image contrast. Additionally, a fraction of patients with [(68)Ga]Ga-pentixafor-positive tumor burden were potentially suitable for CXCR4-directed therapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhenying Chen, Apeng Yang, Jiaying Zhang, Aihong Chen, Yuanqing Zhang, Chao Huang, Shaoming Chen, Shaobo Yao, Weibing Miao
Summary: The study evaluated the value of [(68) Ga]Pentixafor PET/CT for CNSL patients, showing higher accuracy and better contrast compared to [F-18]FDG PET/CT. [(68) Ga]Pentixafor PET/CT detected more lesions and had a higher T/N ratio, making it a promising agent for lesion detection in CNSL patients.
MOLECULAR IMAGING AND BIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andreas K. Buck, Alexander Haug, Niklas Dreher, Alessandro Lambertini, Takahiro Higuchi, Constantin Lapa, Alexander Weich, Martin G. Pomper, Hans-Juergen Wester, Anja Zehndner, Andreas Schirbel, Samuel Samnick, Marcus Hacker, Verena Pichler, Stefanie Hahner, Martin Fassnacht, Hermann Einsele, Sebastian E. Serfling, Rudolf A. Werner
Summary: In recent years, molecular imaging targeting CXCR4 has been increasingly used in various clinical settings. This study aimed to assess radiopharmaceutical uptake and image contrast to determine the clinical applications for CXCR4-directed imaging and investigate the impact of specific activity on scan contrast.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Serkan Kuyumcu, Emine Goknur Isik, Tarik Onur Tiryaki, Duygu Has-Simsek, Yasemin Sanli, Fikret Buyukkaya, Zeynep Gozde Ozkan, Sevgi Kalayoglu-Besisik, Seher Nilgun Unal
Summary: The study found that Ga-68-Pentixafor PET/CT positivity is a negative prognostic factor in the survival outcome of MM patients, and it has the potential to help overcome limitations of F-18-FDG PET/CT and achieve more precise risk stratification.
ANNALS OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Serkan Kuyumcu, Murat Yilmaz Kiran, Evsen Apaydin Arikan, Gulcin Yegen, Yasemin Sanli
Summary: This report evaluates the PET/CT uptake patterns of patients with lymphoproliferative malignancies, finding different uptake characteristics in different subtypes of lymphomas and CLL patients. However, further studies are needed to determine the potential complementary role of [Ga-68]-Pentixafor PET/CT in personalized diagnostic concepts.
CLINICAL AND TRANSLATIONAL IMAGING
(2021)